Amiodarone’s effect on the pharmacokinetics of glibenclamide in healthy and diabetic rats

The purpose of this study is to determine how amiodarone, an antiarrhythmic medication, affects Glibenclamide's hypoglycemic activity in normal and diabetic rats when administered in multiple doses over seven days.

The researchers intended to explore how glibenclamide and amiodarone pharmacologically interact in normal and diabetic rats. These tests were performed on the same group of rats after the provided medications Glibenclamide 1.03 mg/kg body weight and Amiodarone 50 mg/kg body weight had been entirely eliminated, i.e. after the drugs had been totally eliminated. The drugs were administered orally. After taking blood samples from the tail vein at predetermined intervals, the glucose levels were estimated using the GOD/POD technique.

The findings showed that numerous doses of amiodarone, an antiarrhythmic medication, affected the hypoglycaemic action of Glibenclamide in normal and diabetic rats when provided alone and in combination with Glibenclamide. This might be because amiodarone and Glibenclamide have a pharmacokinetic interaction.

Preliminary research suggests that the combination has a pharmacokinetic interaction in diabetic patients with arrhythmia. As a result, blood glucose levels needed to be closely monitored.